|

TTFields Treatment for Mesothelioma: Physician Acceptance is Critical

TTFields treatment for mesothelioma

A new article suggests that non-invasive TTFields treatment for mesothelioma has the potential to save lives – as long as enough physicians accept it. 

TTFields stands for Tumor Treating Fields. It is an electricity-based treatment approved by the FDA for use along with standard mesothelioma chemotherapy

Cancer researchers from West Cancer Center and Research Institute wrote the new article for The Oncologist. They say the success of TTFields treatment for mesothelioma depends on doctors learning the logistics of using it. 

How Does TTFields Treatment for Mesothelioma Work?

TTFields use low-intensity alternating electric fields. When these electric fields hit a mesothelioma tumor, they disrupt normal cell division. If cancer cells cannot divide properly, they are less likely to spread out of control.

TTFields were first used for a brain cancer called glioblastoma. But preclinical data showed mesothelioma cells were especially sensitive to the treatment. 

Eighty patients with unresectable pleural mesothelioma were part of a study released in April. The STELLAR trial showed TTFields treatment for mesothelioma makes chemotherapy more effective. Patients who had both lived six months longer than those who only had chemotherapy. 

Ninety-seven percent of mesothelioma patients in the study had some level of disease control.

Many Doctors Are Still Unfamiliar

TTFields for mesothelioma treatment is the first new therapy approved for asbestos cancer since 2004. But the authors of the new article say many doctors still do not know how to use it in practice.

“Because TTFields are a previously unrecognized antimitotic therapy with a unique mode of delivery, the oncological community must address obstacles to widespread patient and provider acceptance,” they write. 

Pleural mesothelioma patients usually have a combination of surgery and chemotherapy. Some patients may also have radiation. The authors say physicians are not used to the idea of treating cancer patients with an electrical device.

Many cancer patients are also unfamiliar with TTFields treatment for mesothelioma. This may make them reluctant to accept it. 

Physician Understanding of TTFields Treatment for Mesothelioma

Any time a new treatment receives approval, it can take some time for doctors to embrace and start using it. But mesothelioma patients often do not have much time and the data on TTFields treatment for mesothelioma is strong. 

“Physicians need to understand the practical issues surrounding its use,” write the authors. They predict that TTFields will join surgery, chemo and radiation as a main cancer treatment.

To offer TTFields treatment for mesothelioma, a doctor must be trained and certified by Novocure. Mesothelioma patients with implanted devices like pacemakers or defibrillators are not candidates for the treatment.

Source:

Wang, Y, et al, “Integration of Tumor‐Treating Fields into the Multidisciplinary Management of Patients with Solid Malignancies”, August 23, 2019, The Oncologist, Epub ahead of print, http://theoncologist.alphamedpress.org/content/early/2019/08/23/theoncologist.2017-0603

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…